Skip to main content
CriticalFDAfda-F-0599-2024UNDECLARED ALLERGEN

Maggi 2-Minute Noodles; 560g (12 packets per case); plastic pouch; store in a cool dry place

⚠ Critical Alert — Stop Using Immediately

This product has been flagged with severe risks (undeclared allergen). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.

Category
Units Affected
1,200
Recall Date
November 14, 2023
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0599-2024.

Undeclared allergen; peanut

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0599-2024.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact New India Bazar, Inc. or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0599-2024.

New India Bazar, Inc.

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

New India Bazar, Inc. Recall FAQ

New India Bazar, Inc. is the subject of a food safety report: Maggi 2-Minute Noodles; 560g (12 packets per case); plastic pouch; store in a cool dry place. The notice was published on November 14, 2023 by the U.S. Food and Drug Administration (FDA). Approximately 1,200 units are potentially affected.